TABLE 3.
Challenge | Anti-PT IgG titera (μg/ml) on day:
|
Mean WBC count ± SD (103 cells/mm3) on day:
|
||||
---|---|---|---|---|---|---|
0 | 7 | 14 | 0b | 7c | 14c | |
PTx dose (μg) | ||||||
2.5 (n = 13) | 26.5 | 85.0 | 598.0 | 5.9 ± 0.7 | 11.1 ± 2.1 | 17.5 ± 4.3 |
0.5 (n = 12) | 3.3 | 7.8 | 139.3 | 5.5 ± 0.5 | 24.5 ± 3.9 | 30.7 ± 7.5 |
0.1 (n = 12) | 0.8 | 1.1 | 0.7 | 5.2 ± 0.5 | 32.2 ± 3.8 | 171.1 ± 30.6 |
AlPO4 (n = 9) | 0.5 | 0.3 | 0.3 | 5.9 ± 0.4 | 31.5 ± 5.2 | 135.7 ± 64.6 |
Anti-PT IgG titers (presented as geometric means) exhibited dose-dependent characteristics, and differences are significant for all groups and doses (P < 0.05) except between the recipients of the PTx dose of 0.1 μg and the AlPO4 recipients on days 0 and 14 (P > 0.05).
No statistical difference between any of the groups (P > 0.05)
Total WBC counts on days 7 and 14 for the recipients of the PTx dose of 2.5 μg were statistically different from those of lower-dose PTx recipients and AlPO4 recipients (P < 0.01).